×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:CEMI

Chembio Diagnostics Price Target, Predictions & Analyst Ratings

$0.63
-0.02 (-2.92%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.63
$0.66
50-Day Range
$0.45
$0.77
52-Week Range
$0.42
$7.34
Volume
25,300 shs
Average Volume
311,739 shs
Market Capitalization
$19.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Chembio Diagnostics (NASDAQ:CEMI) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 1 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
6/29/21 to 6/29/22
1 Month Ago
5/30/21 to 5/30/22
3 Months Ago
3/31/21 to 3/31/22
1 Year Ago
6/29/20 to 6/29/21
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/A$9.00
Predicted UpsideN/AN/AN/A53.32% Upside
Get Chembio Diagnostics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.


CEMI Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CEMI Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chembio Diagnostics Stock vs. The Competition

TypeChembio DiagnosticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.71
2.51
Consensus RatingHoldBuyBuy
Predicted Upside442.76% Upside33.38% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
273
64.39%
Underperform Votes
151
35.61%
Avg. Outperform Votes
170
67.19%
Avg. Underperform Votes
83
32.81%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical Chembio Diagnostics Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/22/2022Colliers Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
12/3/2020Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Per Ostlund
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$5.00 ➝ $10.00+42.05%
6/17/2020Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Ramsey Schulte
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold$4.00+2.83%
6/17/2020Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeSpeculative Buy ➝ Hold
(Data available from 6/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Chembio Diagnostics Price Target - Frequently Asked Questions

What is Chembio Diagnostics's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Chembio Diagnostics stock is Hold based on the current 1 hold rating for CEMIthe . Learn more on CEMI's analyst rating history.

Do Wall Street analysts like Chembio Diagnostics more than its competitors?

Analysts like Chembio Diagnostics stock less than the stock of other Medical companies. The consensus rating for Chembio Diagnostics is Hold while the average consensus rating for medical companies is Buy. Learn more on how CEMI compares to other companies.

Do MarketBeat users like Chembio Diagnostics more than its competitors?

MarketBeat users like Chembio Diagnostics stock less than the stock of other Medical companies. 64.39% of MarketBeat users gave Chembio Diagnostics an outperform vote while medical companies recieve an average of 67.19% outperform votes by MarketBeat users.

This page (NASDAQ:CEMI) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.